What Comes After Matters: The Importance of Postprogression Care in Patients with Metastatic Hormone-sensitive Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 42493341.
- Also identified by DOI 10.1016/j.eururo.2026.07.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Upfront combination therapy in mHSPC improves outcomes; however, without guaranteed postprogression therapy in control arms, survival benefits may partly reflect undertreatment in the control groups rather than true superiority. Trial designs incorporating planned treatment sequencing are needed to support rational deescalation strategies.